PF-06952229 | m-entrepreneurship.com

Product Name :
PF-06952229

Search keywords :
PF-06952229

drugId :
null

Target Vo:
Transforming growth factor beta receptor 1

Target Vo Short Name :
TGFBR1

Moa_Name:
Transforming growth factor beta receptor 1 inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Pfizer Inc

Active Company_Name :

Active Indication_Name:

In Active Indication_Name:
Liver Neoplasms

Termination Status :
Phase 1 Clinical

China Termination Status :

Highest Status:
Discontinued

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Tozorakimab Interleukin Related
p21 Rabbit mAb In stock
SpI1 Antibody (YA117): SpI1 Antibody (YA117) is a non-conjugated and Rabbit origined monoclonal antibody about 31 kDa, targeting to PU.1/Spi1. It can be used for WB,IHC-P,FC assays with tag free, in the background of Human.

Author: Betaine hydrochloride

Related Posts